C2i Genomics is a company dedicated to improving cancer patient lives and outcomes with a breakthrough tumor pattern recognition approach for liquid biopsy.
C2i Genomics is the first company to develop post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s DNA.
C2i Genomics was founded in 2019 by Asaf Zviran, Boris Oklander and Ezra Sofer. The company is headquartered in New York, New York.
C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. The company's ultra-sensitive liquid biopsy assay will allow physicians to monitor patient treatment response and detect treatment failure or disease recurrence months and potentially years earlier than current monitoring methods.
C2i’s liquid biopsy analysis platform can detect and quantify very small amounts of residual disease in the patient’s blood by utilizing a personalized tumor “fingerprint” representing thousands of mutations for each individual patient.
C2i Genomics has raised $12M in Series A round on June 09, 2020. The financing was led by Casdin Capital and joined by additional new investors including NFX Capital, The Mark Foundation for Cancer Research and other investors.